ResMed (RMD) 10-Q 29 Jan 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Dec. 31, 2013	Jan. 22, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'RESMED INC	'
Entity Central Index Key	'0000943819	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	141,659,731

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$972,675	$876,048
Accounts receivable, net of allowance for doubtful accounts of $12,696 and $9,912 at December 31, 2013 and June 30, 2013, respectively	301,627	318,349
Inventories (note 3)	178,077	145,847
Deferred income taxes	32,721	38,552
Income taxes receivable	3,955	8,910
Prepaid expenses and other current assets	75,077	61,143
Total current assets	1,564,132	1,448,849
Non-current assets:	'	'
Property, plant and equipment, net (note 4)	414,344	411,433
Goodwill and other intangible assets, net (note 6)	336,747	324,468
Deferred income taxes	22,651	20,053
Other assets	7,714	5,918
Total non-current assets	781,456	761,872
Total assets	2,345,588	2,210,721
Current liabilities:	'	'
Accounts payable	56,235	60,688
Accrued expenses	141,946	137,674
Deferred revenue	42,648	44,953
Income taxes payable	1,223	30,090
Deferred income taxes	741	627
Current portion of long-term debt (note 7)	18	300,017
Total current liabilities	242,811	574,049
Non-current liabilities:	'	'
Deferred income taxes	10,274	9,895
Deferred revenue	14,193	11,928
Long-term debt (note 7)	435,794	769
Income taxes payable	3,564	3,564
Total non-current liabilities	463,825	26,156
Total liabilities	706,636	600,205
Commitments and contingencies (note 12)	'	'
Stockholders' equity: (note 10)	'	'
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	'	'
Common stock, $0.004 par value, 350,000,000 shares authorized; 175,593,672 issued and 141,592,659 outstanding at December 31, 2013 and 174,038,766 issued and 142,012,753 outstanding at June 30, 2013	566	568
Additional paid-in capital	1,065,327	1,025,064
Retained earnings	1,673,082	1,576,641
Treasury stock, at cost, 34,001,013 shares at December 31, 2013, and 32,026,013 shares at June 30, 2013	-1,178,946	-1,083,845
Accumulated other comprehensive income	78,923	92,088
Total stockholders' equity	1,638,952	1,610,516
Total liabilities and stockholders' equity	$2,345,588	$2,210,721

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Consolidated Balance Sheets [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$12,696	$9,912
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	175,593,672	174,038,766
Common stock, shares outstanding	141,592,659	142,012,753
Treasury stock, shares held	34,001,013	32,026,013

Consolidated_Statements_Of_Inc

Consolidated Statements Of Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements Of Income [Abstract]	'	'	'	'
Net revenue	$384,341	$376,537	$742,003	$716,269
Cost of sales	135,582	143,825	265,263	274,909
Gross profit	248,759	232,712	476,740	441,360
Operating expenses:	'	'	'	'
Selling, general and administrative	111,748	107,815	213,071	206,118
Research and development	29,537	30,326	56,900	57,546
Amortization of acquired intangible assets	2,454	2,501	4,866	5,138
Total operating expenses	143,739	140,642	274,837	268,802
Income from operations	105,020	92,070	201,903	172,558
Other income, net:	'	'	'	'
Interest income	6,752	8,498	13,166	16,970
Other, net	-2,311	-2,168	-3,539	-227
Total other income, net	4,441	6,330	9,627	16,743
Income before income taxes	109,461	98,400	211,530	189,301
Income taxes	22,825	20,458	43,964	40,094
Net income	$86,636	$77,942	$167,566	$149,207
Basic earnings per share	$0.61	$0.54	$1.18	$1.04
Diluted earnings per share (note 2)	$0.60	$0.53	$1.15	$1.02
Dividend declared per share	$0.25	$0.17	$0.50	$0.34
Basic shares outstanding	142,202	143,214	142,103	142,931
Diluted shares outstanding	145,335	146,689	145,412	146,382

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements Of Comprehensive Income [Abstract]	'	'	'	'
Net income	$86,636	$77,942	$167,566	$149,207
Other comprehensive income:	'	'	'	'
Foreign currency translation gain (loss) adjustments	-51,368	12,163	-13,165	31,020
Comprehensive income	$35,268	$90,105	$154,401	$180,227

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net income	$167,566	$149,207
Adjustment to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	36,450	37,947
Stock-based compensation costs	21,460	17,443
Impairment of cost-method investments	'	225
Foreign currency revaluation	1,970	-377
Excess tax benefit from stock-based compensation arrangements	-9,486	-8,219
Changes in operating assets and liabilities, net of effect of acquisitions:	'	'
Accounts receivable, net	22,061	5,758
Inventories, net	-29,634	-16,497
Prepaid expenses, net deferred income taxes and other current assets	2,094	-2,750
Accounts payable, accrued expenses and other liabilities	-37,891	-10,836
Net cash provided by operating activities	174,590	171,901
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-36,426	-27,635
Patent registration costs	-3,343	-4,801
Business acquisitions, net of cash acquired	-3,172	-5,418
Investments in cost-method investments	-1,525	-891
Purchases of foreign currency options	-405	-500
(Payments)/Proceeds from exercise of foreign currency options	-4,079	8,734
Net cash used in investing activities	-48,950	-30,511
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock, net	10,136	33,308
Excess tax benefit from stock-based compensation arrangements	9,486	8,219
Purchases of treasury stock	-93,592	-48,051
Payment of business combination contingent consideration	-442	-1,641
Proceeds from borrowings, net of borrowing costs	492,908	50,000
Repayment of borrowings	-360,019	-167
Dividend paid	-71,125	-48,688
Net cash used in financing activities	-12,648	-7,020
Effect of exchange rate changes on cash	-16,365	14,369
Net increase in cash and cash equivalents	96,627	148,739
Cash and cash equivalents at beginning of period	876,048	809,541
Cash and cash equivalents at end of period	972,675	958,280
Supplemental disclosure of cash flow information:	'	'
Income taxes paid, net of refunds	61,724	44,234
Interest paid	3,238	2,920
Fair value of assets acquired, excluding cash	2,257	5,970
Liabilities assumed	-829	-2,278
Goodwill on acquisition	3,227	13,876
Deferred payments	-1,483	'
Fair value of contingent consideration	'	-12,150
Total purchase price, excluding contingent consideration	$3,172	$5,418

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	(1)Summary of Significant Accounting Policies
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.
	The condensed consolidated financial statements for the three and six months ended December 31, 2013 and 2012 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2013.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	(2)Earnings Per Share
	Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
	Stock options of 232,176 and 141,320 for the three months ended December 31, 2013 and 2012,  and stock options of 216,558 and 167,903 for the six months ended December 31, 2013 and 2012, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive.
	Basic and diluted earnings per share for the three and six months ended December 31, 2013 and 2012 are calculated as follows (in thousands except per share data):
		Three Months Ended December 31,				Six Months Ended December 31,
		2013		2012		2013		2012
	Numerator:
	Net Income, used in calculating diluted earnings per share	$	86,636	$	77,942	$	167,566	$	149,207
	Denominator:
	Basic weighted-average common shares outstanding		142,202		143,214		142,103		142,931
	Effect of dilutive securities:
	Stock options and restricted stock units		3,133		3,475		3,309		3,451
	Diluted weighted average shares		145,335		146,689		145,412		146,382
	Basic earnings per share	$	0.61	$	0.54	$	1.18	$	1.04
	Diluted earnings per share	$	0.60	$	0.53	$	1.15	$	1.02

Inventories

Inventories	6 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Inventories	'
	(3)Inventories
	Inventories were comprised of the following at December 31, 2013 and June 30, 2013 (in thousands):
		31-Dec-13		30-Jun-13
	Raw materials	$	55,851	$	46,841
	Work in progress		2,255		1,990
	Finished goods		119,971		97,016
	Total inventories	$	178,077	$	145,847

Property_Plant_And_Equipment

Property, Plant And Equipment	6 Months Ended
	Dec. 31, 2013
Property, Plant And Equipment [Abstract]	'
Property, Plant And Equipment	'
	(4)Property, Plant and Equipment
	Property, plant and equipment were comprised of the following as of December 31, 2013 and June 30, 2013 (in thousands):
		31-Dec-13		30-Jun-13
	Machinery and equipment	$	177,120	$	165,782
	Computer equipment		118,879		109,657
	Furniture and fixtures		41,341		40,706
	Vehicles		3,603		3,282
	Clinical, demonstration and rental equipment		104,763		102,304
	Leasehold improvements		29,888		28,466
	Land		60,306		61,091
	Buildings		256,952		260,857
			792,852		772,145
	Accumulated depreciation and amortization		-378,508		-360,712
	Property, plant and equipment, net	$	414,344	$	411,433

CostMethod_Investments

Cost-Method Investments	6 Months Ended
	Dec. 31, 2013
Cost-Method Investments [Abstract]	'
Cost-Method Investments	'
	(5)Cost-Method Investments
	The aggregate carrying amount of our cost-method investments at December 31, 2013 and June 30, 2013, was  $5.5 million and $4.0 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.
	We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values which can be market supported and unobservable inputs including future cash flows.  During the six months ended December 31, 2013 and 2012, we recognized $Nil and $0.2 million, respectively, of impairment losses related to our cost-method investments.  We have determined that the fair value of our investments exceed their carrying values.
	The following table shows a reconciliation of the changes in our cost-method investments during the six months ended December 31, 2013 and 2012 (in thousands):
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	4,000	$	2,250
	Investments		1,525		891
	Impairment of cost-method investments		-		-225
	Balance at the end of the period	$	5,525	$	2,916

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets, Net	6 Months Ended
	Dec. 31, 2013
Goodwill And Other Intangible Assets, Net [Abstract]	'
Goodwill And Other Intangible Assets, Net	'
	(6)Goodwill and Other Intangible Assets, net
	Goodwill
	Changes in the carrying amount of goodwill for the six months ended December 31, 2013, and 2012 were as follows (in thousands):
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	274,829	$	256,209
	Business acquisition		3,227		13,876
	Foreign currency translation adjustments		11,989		9,299
	Balance at the end of the period	$	290,045	$	279,384
	Other Intangible Assets
	Other intangible assets are comprised of the following as of December 31, 2013,  and June 30, 2013 (in thousands):
		31-Dec-13		June 30, 2013
	Developed/core product technology	$	75,399	$	72,698
	Accumulated amortization		-50,671		-45,492
	Developed/core product technology, net		24,728		27,206
	Trade names		2,786		2,662
	Accumulated amortization		-2,698		-2,491
	Trade names, net		88		171
	Non-compete agreements		2,023		2,068
	Accumulated amortization		-1,457		-1,265
	Non compete agreements, net		566		803
	Customer relationships		24,219		22,291
	Accumulated amortization		-19,206		-17,095
	Customer relationships, net		5,013		5,196
	Patents		62,362		59,962
	Accumulated amortization		-46,055		-43,699
	Patents, net		16,307		16,263
	Total other intangibles, net	$	46,702	$	49,639
	Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology.  We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2013
Long-Term Debt [Abstract]	'
Long-Term Debt	'
	(7)Long-Term Debt
	Long-term debt at December 31, 2013 and June 30, 2013 consists of the following (in thousands):
		31-Dec-13		June 30, 2013
	Current long-term debt	$	18	$	300,017
	Non-current long-term debt		435,794		769
	Total long-term debt	$	435,812	$	300,786
	Credit Facility
	On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.
	The credit agreement provides a $700 million senior unsecured five-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $300 million. The credit facility also includes a $25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At December 31, 2013, the interest rate that was being charged on the outstanding principal amount was 1.2%.    An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.
	When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previously existing revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previously-existing credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and L/C Issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under the previously existing credit agreement were also terminated.
	Our obligations under the new credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC.
	At December 31, 2013, there was $435.0 million outstanding under the credit agreement.

Product_Warranties

Product Warranties	6 Months Ended
	Dec. 31, 2013
Product Warranties [Abstract]	'
Product Warranties	'
	(8)Product Warranties
	Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the six months ended December 31, 2013 and 2012 are as follows (in thousands):
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	16,011	$	17,018
	Warranty accruals for the period		4,425		7,262
	Warranty costs incurred for the period		-4,500		-5,627
	Foreign currency translation adjustments		-252		123
	Balance at the end of the period	$	15,684	$	18,776

StockBased_Employee_Compensati

Stock-Based Employee Compensation	6 Months Ended
	Dec. 31, 2013
Stock-Based Employee Compensation [Abstract]	'
Stock-Based Employee Compensation	'
	(9)Stock-Based Employee Compensation
	We measure the compensation expense of all stock-based awards at fair value on the grant date.  We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period.  We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.
	We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:
		Three Months Ended December 31,				Six Months Ended December 31,
		2013		2012		2013		2012
	Stock options:
	Weighted average grant date fair value	$	10.9	$	9.38	$	10.9	$	9.34
	Weighted average risk-free interest rate		1.44%		0.61%		1.44%		0.61%
	Expected option life in years		4.9		4.9		4.9		4.9
	Dividend yield		2.06%		1.74%		2.06%		1.75%
	Expected volatility		30%		33%		30%		33%
	ESPP purchase rights:
	Weighted average risk-free interest rate		0.08%		0.15%		0.08%		0.15%
	Expected option life in years		6 months		6 months		6 months		6 months
	Dividend yield		1.44% - 1.96%		1.67%		1.44% - 1.96%		1.67%
	Expected volatility		24% - 28%		27% - 30%		24% - 28%		27% - 30%
	During the six months ended December 31, 2013 and 2012, we also granted performance restricted stock units (“PRSUs”), which contain a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a three-year period, up to a maximum amount to be issued under the award of 200% of the original grant. The weighted average fair value of PRSUs granted during the six months ended December 31, 2013 and 2012 was estimated at $50.09 and $37.87 per PRSU, respectively, using a Monte-Carlo simulation valuation model.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	(10)Stockholders’ Equity
	Common Stock.    On August 24, 2011, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of ResMed Inc. common stock.  The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant.  There is no expiration date for this program.  All share repurchases since August 24, 2011 have been executed in accordance with this program.
	During the three and six months ended December 31, 2013, we repurchased 1.5 million and 2.0 million shares at a cost of $74.0 million and $95.1 million, respectively. Since the inception of our share repurchase programs and through December 31, 2013, we have repurchased a total of 34.0 million shares at a cost of $1.2 billion.  Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.  At December 31, 2013,  2.6 million additional shares can be repurchased under the approved share repurchase program.
	Preferred Stock.    In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No such shares were issued or outstanding at December 31, 2013 and June 30, 2013.
	Stock Options and Restricted Stock Units.    We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”).  These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.
	At the annual meeting of our stockholders on November 13, 2013, our stockholders approved an amendment to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 8.3 million shares to 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at December 31, 2013 is  16.1 million.  The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards.  The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring up to 4.5 million shares of our common stock may be granted).
	At December 31, 2013, there was $97.0 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.6 years.  The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at December 31, 2013 was $254.0 million and $120.4 million, respectively.  The aggregate intrinsic value of the options exercised during the six months ended December 31, 2013 and 2012, was $50.5 million and $36.2 million, respectively.
	The following table summarizes option activity during the six months ended December 31, 2013:
			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	6,316,136	$	22.68	3.1
	Granted	161,005		48.56
	Exercised	-745,512		19.74
	Forfeited	-37,675		39.60
	Outstanding at end of period	5,693,954	$	23.69	2.8
	Exercise price range of granted options	46.15 - 51.25
	Options exercisable at end of period	4,555,349	$	20.66
	The following table summarizes the activity of restricted stock units during the six months ended December 31, 2013:
			Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	2,633,407	$	33.25	1.4
	Granted	839,647		46.68
	Vested	-876,530		31.42
	Forfeited	-38,049		32.43
	Outstanding at end of period	2,558,475	$	38.29	1.8
	Employee Stock Purchase Plan (the “ESPP”).  Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year.  At December 31, 2013, the number of shares remaining available for future issuance under the ESPP is  1.9 million shares.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	(11)Fair Value Measurements
	In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability.  We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The hierarchies of inputs are as follows:
		·		Level 1:Input prices quoted in an active market for identical financial assets or liabilities;
		·		Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and
		·		Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.
	The following table summarizes our financial assets and liabilities, as at December 31, 2013 and June 30, 2013, using the valuation input hierarchy (in thousands):
			Level 1		Level 2		Level 3		Total
	Balances at December 31, 2013
	Foreign currency hedging instruments, net	$	-	$	-16,667	$	-	$	-16,667
	Business acquisition contingent consideration	$	-	$	-	$	-4,043	$	-4,043
	Balances at June 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
	Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
	We determine the fair value of our financial assets and liabilities as follows:
	Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.
	Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones.  Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.
	The following is a reconciliation of changes in the fair value of contingent consideration for the six months ended December 31, 2013 (in thousands):
		Six Months Ended December 31, 2013
	Balance at the beginning of the period	$	-7,779
	Acquisition date fair value of contingent consideration		-
	Changes in fair value included in operating income		3,438
	Payments		442
	Foreign currency translation adjustments		-144
	Balance at the end of the period	$	-4,043
	We did not have any significant non-financial assets or liabilities measured at fair value on December 31, 2013 or June 30, 2013.

Legal_Actions_And_Contingencie

Legal Actions And Contingencies	6 Months Ended
	Dec. 31, 2013
Legal Actions And Contingencies [Abstract]	'
Legal Actions And Contingencies	'
	(12)Legal Actions and Contingencies
	Litigation
	In the normal course of business, we are subject to routine litigation incidental to our business.  While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
	In March 2013, we filed parallel legal actions in the International Trade Commission, or ITC, and in U.S. district court against Taiwanese manufacturer APEX to stop the infringement of several ResMed patents.  In August 2013, the ITC entered a consent decree against APEX, ordering that it not import or sell after import products that infringe the claims of the patents that ResMed asserted against APEX.  Thereafter, APEX initiated inter partes review proceedings in the U.S. Patent and Trademark Office, challenging the validity of most of the claims asserted against APEX in the ITC.  The U.S. district court has stayed the litigation against APEX pending the resolution of the inter partes review.  APEX has also advised the ITC that is has redesigned the accused products and requested that the ITC determine whether those products are subject to the consent decree.  The ITC has referred APEX’s request to an administrative law judge for an initial determination on the question of infringement.  Therefore the matter is ongoing as to APEX.   However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.
	In June 2013, we filed a lawsuit in U.S. district court against Chinese manufacturer BMC Medical Co., Ltd and its U.S. distributor to stop the infringement of several ResMed patents.  In July 2013, we amended the district court lawsuit, and filed a parallel proceeding in the ITC.  The ITC initiated an investigation of BMC’s alleged infringement in August 2013, and that matter is proceeding.  The district court lawsuit has been stayed by the court pending the conclusion of the ITC proceeding.  Therefore the matter is ongoing as to BMC.  However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.
	In November 2013, we obtained preliminary injunctions prohibiting APEX and BMC from marketing and selling certain products accused of patent infringement in Germany.  The orders, entered by the Munich District Court, prohibit APEX and BMC from selling those products without a further court order.  ResMed also filed separate actions seeking damages from each defendant.  APEX and BMC have informed the court that they will contest the injunctions and the actions for damages.  Therefore the matter is ongoing.  However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Activities	6 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities [Abstract]	'
Derivative Instruments And Hedging Activities	'
	(13)Derivative Instruments and Hedging Activities
	We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations.  We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows.  The terms of such foreign currency hedging contracts generally do not exceed three years.  The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars.  Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.
	We do not designate these foreign currency contracts as hedges.  We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance.  All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income.  We do not enter into financial instruments for trading or speculative purposes.
	We held foreign currency instruments with notional amounts totaling $412.7 million and $462.1 million at December 31, 2013 and June 30, 2013, respectively, to hedge foreign currency fluctuations.  These contracts mature at various dates prior to December 31, 2016.
	The following table summarizes the amount and location of our derivative financial instruments as of December 31, 2013 and June 30, 2013 (in thousands):
		31-Dec-13		30-Jun-13		Balance Sheet Caption
	Foreign currency hedging instruments	$	71	$	1,350		Other assets - current
	Foreign currency hedging instruments		169		657		Other assets - non current
	Foreign currency hedging instruments		-16,907		-9,007		Accrued expenses
		$	-16,667	$	-7,000
	The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the six months ended December 31, 2013 and December 31, 2012, respectively (in thousands):
		Gain /(Loss) Recognized				Income Statement Caption
		Six Months Ended December 31,
		2013		2012
	Foreign currency hedging instruments	$	-14,459	$	-1,845		Other, net
	Other foreign-currency-denominated transactions		10,621		1,759		Other, net
		$	-3,838	$	-86
	We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments.  We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	6 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Organization And Basis Of Presentation	'
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.
	The condensed consolidated financial statements for the three and six months ended December 31, 2013 and 2012 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2013.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule Of Basic And Diluted Earnings Per Share	'
		Three Months Ended December 31,				Six Months Ended December 31,
		2013		2012		2013		2012
	Numerator:
	Net Income, used in calculating diluted earnings per share	$	86,636	$	77,942	$	167,566	$	149,207
	Denominator:
	Basic weighted-average common shares outstanding		142,202		143,214		142,103		142,931
	Effect of dilutive securities:
	Stock options and restricted stock units		3,133		3,475		3,309		3,451
	Diluted weighted average shares		145,335		146,689		145,412		146,382
	Basic earnings per share	$	0.61	$	0.54	$	1.18	$	1.04
	Diluted earnings per share	$	0.60	$	0.53	$	1.15	$	1.02

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Schedule Of Inventories	'
		31-Dec-13		30-Jun-13
	Raw materials	$	55,851	$	46,841
	Work in progress		2,255		1,990
	Finished goods		119,971		97,016
	Total inventories	$	178,077	$	145,847

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	6 Months Ended
	Dec. 31, 2013
Property, Plant And Equipment [Abstract]	'
Components Of Property, Plant And Equipment	'
		31-Dec-13		30-Jun-13
	Machinery and equipment	$	177,120	$	165,782
	Computer equipment		118,879		109,657
	Furniture and fixtures		41,341		40,706
	Vehicles		3,603		3,282
	Clinical, demonstration and rental equipment		104,763		102,304
	Leasehold improvements		29,888		28,466
	Land		60,306		61,091
	Buildings		256,952		260,857
			792,852		772,145
	Accumulated depreciation and amortization		-378,508		-360,712
	Property, plant and equipment, net	$	414,344	$	411,433

CostMethod_Investments_Tables

Cost-Method Investments (Tables)	6 Months Ended
	Dec. 31, 2013
Cost-Method Investments [Abstract]	'
Schedule Of Reconciliation Of Changes In Cost-Method Investments	'
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	4,000	$	2,250
	Investments		1,525		891
	Impairment of cost-method investments		-		-225
	Balance at the end of the period	$	5,525	$	2,916

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets, Net (Tables)	6 Months Ended
	Dec. 31, 2013
Goodwill And Other Intangible Assets, Net [Abstract]	'
Schedule Of Changes In Carrying Amount Of Goodwill	'
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	274,829	$	256,209
	Business acquisition		3,227		13,876
	Foreign currency translation adjustments		11,989		9,299
	Balance at the end of the period	$	290,045	$	279,384
Schedule Of Other Intangible Assets	'
		31-Dec-13		June 30, 2013
	Developed/core product technology	$	75,399	$	72,698
	Accumulated amortization		-50,671		-45,492
	Developed/core product technology, net		24,728		27,206
	Trade names		2,786		2,662
	Accumulated amortization		-2,698		-2,491
	Trade names, net		88		171
	Non-compete agreements		2,023		2,068
	Accumulated amortization		-1,457		-1,265
	Non compete agreements, net		566		803
	Customer relationships		24,219		22,291
	Accumulated amortization		-19,206		-17,095
	Customer relationships, net		5,013		5,196
	Patents		62,362		59,962
	Accumulated amortization		-46,055		-43,699
	Patents, net		16,307		16,263
	Total other intangibles, net	$	46,702	$	49,639

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Dec. 31, 2013
Long-Term Debt [Abstract]	'
Schedule Of Long-Term Debt	'
		31-Dec-13		June 30, 2013
	Current long-term debt	$	18	$	300,017
	Non-current long-term debt		435,794		769
	Total long-term debt	$	435,812	$	300,786

Product_Warranties_Tables

Product Warranties (Tables)	6 Months Ended
	Dec. 31, 2013
Product Warranties [Abstract]	'
Schedule Of Changes In Liability For Warranty Costs	'
		Six Months Ended December 31,
		2013		2012
	Balance at the beginning of the period	$	16,011	$	17,018
	Warranty accruals for the period		4,425		7,262
	Warranty costs incurred for the period		-4,500		-5,627
	Foreign currency translation adjustments		-252		123
	Balance at the end of the period	$	15,684	$	18,776

StockBased_Employee_Compensati1

Stock-Based Employee Compensation (Tables)	6 Months Ended
	Dec. 31, 2013
Stock-Based Employee Compensation [Abstract]	'
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	'
		Three Months Ended December 31,				Six Months Ended December 31,
		2013		2012		2013		2012
	Stock options:
	Weighted average grant date fair value	$	10.9	$	9.38	$	10.9	$	9.34
	Weighted average risk-free interest rate		1.44%		0.61%		1.44%		0.61%
	Expected option life in years		4.9		4.9		4.9		4.9
	Dividend yield		2.06%		1.74%		2.06%		1.75%
	Expected volatility		30%		33%		30%		33%
	ESPP purchase rights:
	Weighted average risk-free interest rate		0.08%		0.15%		0.08%		0.15%
	Expected option life in years		6 months		6 months		6 months		6 months
	Dividend yield		1.44% - 1.96%		1.67%		1.44% - 1.96%		1.67%
	Expected volatility		24% - 28%		27% - 30%		24% - 28%		27% - 30%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Schedule Of Option Activity	'
			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	6,316,136	$	22.68	3.1
	Granted	161,005		48.56
	Exercised	-745,512		19.74
	Forfeited	-37,675		39.60
	Outstanding at end of period	5,693,954	$	23.69	2.8
	Exercise price range of granted options	46.15 - 51.25
	Options exercisable at end of period	4,555,349	$	20.66
Schedule Of Activity Of Restricted Stock Units	'
			Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	2,633,407	$	33.25	1.4
	Granted	839,647		46.68
	Vested	-876,530		31.42
	Forfeited	-38,049		32.43
	Outstanding at end of period	2,558,475	$	38.29	1.8

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Summary Of Financial Assets And Liabilities	'
			Level 1		Level 2		Level 3		Total
	Balances at December 31, 2013
	Foreign currency hedging instruments, net	$	-	$	-16,667	$	-	$	-16,667
	Business acquisition contingent consideration	$	-	$	-	$	-4,043	$	-4,043
	Balances at June 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
	Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	'
		Six Months Ended December 31, 2013
	Balance at the beginning of the period	$	-7,779
	Acquisition date fair value of contingent consideration		-
	Changes in fair value included in operating income		3,438
	Payments		442
	Foreign currency translation adjustments		-144
	Balance at the end of the period	$	-4,043

Derivative_Instruments_And_Hed1

Derivative Instruments And Hedging Activities (Tables)	6 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities [Abstract]	'
Summary Of Amount And Location Of Derivative Financial Instruments	'
		31-Dec-13		30-Jun-13		Balance Sheet Caption
	Foreign currency hedging instruments	$	71	$	1,350		Other assets - current
	Foreign currency hedging instruments		169		657		Other assets - non current
	Foreign currency hedging instruments		-16,907		-9,007		Accrued expenses
		$	-16,667	$	-7,000
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	'
		Gain /(Loss) Recognized				Income Statement Caption
		Six Months Ended December 31,
		2013		2012
	Foreign currency hedging instruments	$	-14,459	$	-1,845		Other, net
	Other foreign-currency-denominated transactions		10,621		1,759		Other, net
		$	-3,838	$	-86

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'
Stock options not included in the computation of diluted earnings per share	232,176	141,320	216,558	167,903

Earnings_Per_Share_Schedule_Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'
Net Income, used in calculating diluted earnings per share	$86,636	$77,942	$167,566	$149,207
Basic weighted-average common shares outstanding	142,202	143,214	142,103	142,931
Effect of dilutive securities, stock options and restricted stock units	3,133	3,475	3,309	3,451
Diluted weighted average shares	145,335	146,689	145,412	146,382
Basic earnings per share	$0.61	$0.54	$1.18	$1.04
Diluted earnings per share	$0.60	$0.53	$1.15	$1.02

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$55,851	$46,841
Work in progress	2,255	1,990
Finished goods	119,971	97,016
Total inventories	$178,077	$145,847

Property_Plant_And_Equipment_D

Property, Plant And Equipment (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$792,852	$772,145
Accumulated depreciation and amortization	-378,508	-360,712
Property, plant and equipment, net	414,344	411,433
Machinery And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	177,120	165,782
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	118,879	109,657
Furniture And Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	41,341	40,706
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	3,603	3,282
Clinical, Demonstration And Rental Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	104,763	102,304
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	29,888	28,466
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	60,306	61,091
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$256,952	$260,857

CostMethod_Investments_Narrati

Cost-Method Investments (Narrative) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2012
Cost-Method Investments [Abstract]	'	'	'	'
Aggregate carrying amount of cost-method investments	$2,916	$5,525	$4,000	$2,250
Write-down of cost-method investments	$225	'	'	'

CostMethod_Investments_Schedul

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cost-Method Investments [Abstract]	'	'
Balance at the beginning of the period	$4,000	$2,250
Investments	1,525	891
Impairment of cost-method investments	'	-225
Balance at the end of the period	$5,525	$2,916

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Other Intangible Assets, Net [Abstract]	'	'
Balance at the beginning of the period	$274,829	$256,209
Business acquisition	3,227	13,876
Foreign currency translation adjustments	11,989	9,299
Balance at the end of the period	$290,045	$279,384

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) (USD $)

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

In Thousands, unless otherwise specified

Developed/Core Product Technology [Member]

Developed/Core Product Technology [Member]

Trade Names [Member]

Trade Names [Member]

Non Compete Agreements [Member]

Non Compete Agreements [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Patents [Member]

Patents [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangibles, gross

'

'

$75,399

$72,698

$2,786

$2,662

$2,023

$2,068

$24,219

$22,291

$62,362

$59,962

'

'

Accumulated amortization

'

'

-50,671

-45,492

-2,698

-2,491

-1,457

-1,265

-19,206

-17,095

-46,055

-43,699

'

'

Total other intangibles, net

$46,702

$49,639

$24,728

$27,206

$88

$171

$566

$803

$5,013

$5,196

$16,307

$16,263

'

'

Intangible assets, estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'9 years

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	6 Months Ended
	Dec. 31, 2013	Oct. 31, 2013
Line of Credit Facility [Line Items]	'	'
Amount outstanding under credit facility	$435,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility termination date	31-Oct-18	'
Interest rate on outstanding principal amount	1.20%	'
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	700,000,000
Credit facility term, years	'5 years	'
Uncommitted option to increase credit facility	300,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	$25,000,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.15%	'
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	1.00%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.25%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	2.00%	'

LongTerm_Debt_Schedule_Of_Long

Long-Term Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Long-Term Debt [Abstract]	'	'
Current long-term debt	$18	$300,017
Non-current long-term debt	435,794	769
Total long-term debt	$435,812	$300,786

Product_Warranties_Details

Product Warranties (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Product Warranties [Abstract]	'	'
Balance at the beginning of the period	$16,011	$17,018
Warranty accruals for the period	4,425	7,262
Warranty costs incurred for the period	-4,500	-5,627
Foreign currency translation adjustments	-252	123
Balance at the end of the period	$15,684	$18,776

StockBased_Employee_Compensati2

Stock-Based Employee Compensation (Narrative) (Details) (Performance Shares [Member], USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Performance Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shareholder return period	'3 years	'
Maximum amount of restricted stock units to be issued, percentage of the original grant	200.00%	'
Fair value of equity instruments other than options granted	$50.09	$37.87

StockBased_Employee_Compensati3

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average grant date fair value	$10.90	$9.38	$10.90	$9.34
Weighted average risk-free interest rate	1.44%	0.61%	1.44%	0.61%
Expected option life in years	'4 years 10 months 24 days	'4 years 10 months 24 days	'4 years 10 months 24 days	'4 years 10 months 24 days
Dividend yield	2.06%	1.74%	2.06%	1.75%
Expected volatility	30.00%	33.00%	30.00%	33.00%
ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average risk-free interest rate	0.08%	0.15%	0.08%	0.15%
Expected option life in years	'6 months	'6 months	'6 months	'6 months
Dividend yield	'	1.67%	'	1.67%
Expected volatility, minimum	24.00%	27.00%	24.00%	27.00%
Expected volatility, maximum	28.00%	30.00%	28.00%	30.00%
Minimum [Member] | ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Dividend yield	1.44%	'	1.44%	'
Maximum [Member] | ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Dividend yield	1.96%	'	1.96%	'

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

139 Months Ended

0 Months Ended

6 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2013

Aug. 24, 2011

Apr. 30, 1997

Nov. 13, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized to be repurchased under repurchase program

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

Common shares repurchased

1,500,000

2,000,000

'

34,000,000

'

'

'

'

'

'

'

'

'

Cost of common shares repurchased

$74,000,000

$95,100,000

'

$1,200,000,000

'

'

'

'

'

'

'

'

'

Additional shares that can be repurchased under the approved share repurchase program

2,600,000

2,600,000

'

2,600,000

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

2,000,000

2,000,000

'

2,000,000

2,000,000

'

2,000,000

'

'

'

'

'

'

Preferred stock at par value

$0.01

$0.01

'

$0.01

$0.01

'

$0.01

'

'

'

'

'

'

Preferred stock, shares issued

0

0

'

0

0

'

'

'

'

'

'

'

'

Preferred stock, shares outstanding

0

0

'

0

0

'

'

'

'

'

'

'

'

Stock option and restricted stock units expiration period

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

Stock options and restricted stock units vesting period

'

'

'

'

'

'

'

'

'

'1 year

'

'4 years

'

Number of additional shares authorized

'

'

'

'

'

'

'

8,300,000

'

'

'

'

'

Common stock authorized for issuance

43,700,000

43,700,000

'

43,700,000

'

'

'

'

'

'

'

'

'

Number of securities remaining available for future issuance

16,100,000

16,100,000

'

16,100,000

'

'

'

'

1,900,000

'

'

'

'

Reduction in the number of shares of common stock available for issuance

2.8

2.8

'

2.8

'

'

'

'

'

'

'

'

'

Maximum number of shares subject to awards granted

3,000,000

3,000,000

'

3,000,000

'

'

'

'

'

'

'

'

'

Number of common stock shares granted in participant's initial year of hiring

4,500,000

4,500,000

'

4,500,000

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to unvested stock-based compensation arrangements

97,000,000

97,000,000

'

97,000,000

'

'

'

'

'

'

'

'

'

Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements

'

'2 years 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the stock-based compensation arrangements outstanding

254,000,000

254,000,000

'

254,000,000

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the stock-based compensation arrangements exercisable

120,400,000

120,400,000

'

120,400,000

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the options exercised

'

50,500,000

36,200,000

'

'

'

'

'

'

'

'

'

'

Employee stock purchase program offering period

'

'

'

'

'

'

'

'

'

'

'3 months

'

'27 months

Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

Common stock shares subscribed

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Option Activity) (Details) (USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Outstanding at beginning of period	6,316,136	'
Options, Granted	161,005	'
Options, Exercised	-745,512	'
Options, Forfeited	-37,675	'
Options, Outstanding at end of period	5,693,954	6,316,136
Options exercisable at end of period	4,555,349	'
Weighted Average Exercise Price, Outstanding at beginning of period	$22.68	'
Weighted Average Exercise Price, Granted	$48.56	'
Weighted Average Exercise Price, Exercised	$19.74	'
Weighted Average Exercise Price, Forfeited	$39.60	'
Weighted Average Exercise Price, Outstanding at end of period	$23.69	$22.68
Weighted Average Exercise Price, Options exercisable at end of period	$20.66	'
Weighted Average Remaining Term to Vest in Years, Outstanding	'2 years 9 months 18 days	'3 years 1 month 6 days
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Exercise price range of granted options	$46.15	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Exercise price range of granted options	$51.25	'

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Restricted Stock Units, Outstanding at beginning of period	2,633,407	'
Restricted Stock Units, Granted	839,647	'
Restricted Stock Units, Vested	-876,530	'
Restricted Stock Units, Forfeited	-38,049	'
Restricted Stock Units, Outstanding at end of period	2,558,475	2,633,407
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$33.25	'
Weighted Average Grant-Date Fair Value, Granted	$46.68	'
Weighted Average Grant-Date Fair Value, Vested	$31.42	'
Weighted Average Grant-Date Fair Value, Forfeited	$32.43	'
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$38.29	$33.25
Weighted Average Remaining Contractual Term in Years, Outstanding	'1 year 9 months 18 days	'1 year 4 months 24 days

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	($16,667)	($7,000)
Business acquisition contingent consideration	-4,043	-7,779
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	'	'
Business acquisition contingent consideration	'	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	-16,667	-7,000
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business acquisition contingent consideration	($4,043)	($7,779)

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Balance at the beginning of the period	($7,779)
Acquisition date fair value of contingent consideration	'
Changes in fair value included in operating income	3,438
Payments	442
Foreign currency translation adjustments	-144
Balance at the end of the period	($4,043)

Derivative_Instruments_And_Hed2

Derivative Instruments And Hedging Activities (Narrative) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013
In Millions, unless otherwise specified			Foreign Currency Contracts [Member]
Derivative [Line Items]	'	'	'
Terms of foreign currency hedging contracts, maximum	'	'	'3 years
Notional amount of foreign currency hedging contracts held	$412.70	$462.10	'

Derivative_Instruments_And_Hed3

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) (Foreign Currency Contracts [Member], USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets (Liabilities)	($16,667)	($7,000)
Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	71	1,350
Other Noncurrent Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	169	657
Accrued Expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Liabilities	($16,907)	($9,007)

Derivative_Instruments_And_Hed4

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) (Derivatives Not Designated As Hedging Instruments [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in Income	($3,838)	($86)
Foreign Currency Contracts [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Foreign currency-hedging instruments	-14,459	-1,845
Other Foreign-currency-denominated Transactions [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Other foreign-currency-denominated transactions	$10,621	$1,759